KKR joins investors in biotherapeutics developer Coherus BioSciences

Coherus BioSciences, a US biologics platform company focused on biosimilars, has closed a Series C round raising $55m from investors including KKR, Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences.